Positioned for Growth
|
|
- Myles Summers
- 5 years ago
- Views:
Transcription
1 Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient
2 This presentation contains forward looking statements, which are generally statements that are not historical facts. Forward looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward looking statement in light of new information or future events, except as otherwise required by law. Forward looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10 K and our other reports filed with the Securities and Exchange Commission. 2
3 Where we are today Rapid progress in transforming company strategy, culture and financial position Projected cash balance at 12/31/16: $ million Product Revenue growth Q to Q1 2016: +41% Product and royalty revenue guidance for 2016 given on May 10, 2016 $170 $180 million OPEX guidance at $ mil reduced from previously planned ~$400 mil Clear vision, building from core strengths in precision small molecule therapies and rare cancers Positioned for potential increase in addressable patient population from 1,000 2,000 to approx. 16,000 18,000 patients: Rapid near term revenue growth through potentially becoming a two product commercial company by early 2017 Mid term revenue growth from potential market expansion of Iclusig and brigatinib Longer term growth potential from AP32788 and new opportunities from discovery platform, including immuno oncology program 3
4 Our Vision is to become the leader in the discovery, development, and commercialization of precision therapies for patients with rare cancers. 4
5 Core strength: Precision therapies Precisely designed to address mutational resistance and drive differential efficacy Precisely defined groups of patients who have limited options and can receive greatest benefit Iclusig Survival Probability Common EGFR mutations EGFR exon 20 insertions 96 Brigatinib AP32788 Survival in months 5
6 Core strength: Rare cancers Currently account for around a quarter of all cancer diagnoses and deaths* Expected to increase in importance as more molecular subsets of common cancers are identified * Incident Number of Patients (US) 200,000 Orphan Threshold (prevalence) ARIAD Focus: 45,000 Rare Cancer Threshold ** Address rare cancers/patient populations with high value precision therapies Patient centric development and commercial model *Lancet, February 2016 **NCI Epidemiology and Genetics Research ARIAD Current/Potential Markets 8,000 ALK+NSCLC 6,000 Exon 20 EGFR/HER2 NSCLC 3,300 CML/Ph+ALL 6
7 Strategic review: Areas of focus Geographic Reach Commercial Maximization R&D Portfolio Cost Efficiencies Business Development 7
8 Strategic review: Approach and methodology Rigorous, quantitative approach Evaluation of options based on Risk adjusted NPVs Impact on cash/financial flexibility Projected value of business over time factoring in key milestones Incorporated perspective from a range of stakeholders Company Valuation (rnpv) Cost Re focus Efficiencies on US Commercial Prior to Maximization Strategic Review Illustrative Approach After Strategic Review APAP32788 Brigatinib Clinical Approval/ Data Launch ALTA 1L Data OPTIC/2L Data Potential Future Value 8
9 Strategic review: Actions taken to date Incyte Transaction Kick off Strategic Review Cost Efficiencies: Reductions to expense base Iclusig EU License & Co development Divestiture of EU Operation z z z z Incyte Transaction Closing z Brigatinib NDA Initiated LATAM/ MENA distributor deal z 9
10 ARIAD s new strategy Commercial Maximization Development/Pipeline Science & Discovery Lean, Cost efficient Structure US direct commercialization Leverage Iclusig to continue growth Planned successful 2017 launch of brigatinib (subject to FDA approval) Ex US revenues with minimal costs partnerships with strategic optionality Earlier lines of treatment for brigatinib and Iclusig AP32788 EGFR/HER2 lung cancer Share development costs through ex US partnerships Engine for new potential products expand development pipeline World class capability in designing precision cancer therapies Expanding platform into small molecule immuno oncology Rare cancer model designed for efficient commercialization/r&d Operations limited to US Lean G&A/headquarter functions 10
11 ARIAD s new strategy Commercial Maximization US direct commercialization Leverage Iclusig to continue growth Planned successful 2017 launch of brigatinib (subject to FDA approval) Ex US revenues with minimal costs partnerships with strategic optionality Development/Pipeline Science & Discovery Lean, Cost efficient Structure 11
12 COMMERCIAL MAXIMIZATION New geographic strategy: US focus with global reach through partners Rationale US represents majority of industry oncology profits based on ~50% of global sales Can retain significant share of ex US value through partnerships Strive to maintain strategic optionality 12
13 COMMERCIAL MAXIMIZATION Incyte transaction: Execution of new strategy Key Terms Incyte acquired ARIAD EU operations and licensed Iclusig for the region (EU countries plus others, including Russia, Turkey) Financials: $140 mil upfront & 32 50% royalties to ARIAD $14 mil in development cost sharing for OPTIC/OPTIC2L $135 mil potential milestones in oncology indications ARIAD acquirer may terminate license following change of control Incyte receives financial payments & ongoing royalty from acquirer Major Benefits Significantly improves cash position/financial profile Operating costs reduced by ~ $65 mil annually Continuity of Iclusig commercialization ongoing ARIAD royalties Strategic flexibility 13
14 COMMERCIAL MAXIMIZATION Iclusig Katie Olson Chronic myeloid leukemia Iclusig patient 14
15 COMMERCIAL MAXIMIZATION Iclusig: Growth is expected to continue Iclusig Global Sales & Royalties $200M $150M $100M $50M CAGR +77% Key Drivers of Future Growth Field team expansion 4 year PACE data; expected label update Increasing clinical experience Patient retention programs Actual 2015 Actual 2016 Guidance 15
16 COMMERCIAL MAXIMIZATION Brigatinib BRIGATINIB Andy Bonnet Non small cell lung cancer ARIAD clinical trial patient 16
17 COMMERCIAL MAXIMIZATION Brigatinib: Overview BRIGATINIB NDA submission initiated in crizotinib resistant ALK+ NSCLC in June 2016 NDA completion planned for Q Breakthrough designation from FDA Pivotal data suggests differentiated efficacy PFS 12.9 months * (vs. competitors 6 9 months) Preparing for anticipated US launch in early 2017 Development for front line indication under way *Secondary endpoint, comparison not head to head 17
18 COMMERCIAL MAXIMIZATION 2016 Global ALK inhibitor market: Annualized market approaching $800 mil In Millions $ $900.0 $800.0 $700.0 $600.0 $500.0 $400.0 $300.0 Global ALK Inhibitor Market $632 $349 Ex US $768 $420 Ex US Analysts projecting market growth toward ~$2 billion by % Q1/16 vs. Q1/15 growth $200.0 $100.0 $283 $348 US US $ Q Annualized Source: Pfizer 2016 Q1 Performance For Xalkori, Novartis 2016 Q1 Performance for Zykadia, Roche 2016 Q1 Performance for Alecensa 18
19 ARIAD s new strategy Commercial Maximization Development/Pipeline Earlier lines of treatment for brigatinib and Iclusig AP32788 EGFR/HER2 lung cancer Share development costs through ex US partnerships Science & Discovery Lean, Cost efficient Structure 19
20 DEVELOPMENT/PIPELINE Core development programs Iclusig Brigatinib AP32788 OPTIC & OPTIC 2L ALTA and ALTA 1L Phase I/II 20
21 DEVELOPMENT/PIPELINE Iclusig: Development programs OPTIC & OPTIC 2L Goals Improve Iclusig safety profile through lower doses Expand market potential through earlier lines of treatment 2L indication more than doubles available market Demonstrate superior efficacy to drive market share 1st Line 6,000 2nd Line 1,900 3rd Line 920 Other Considerations Incyte partnership provides $14 million funding, plus significant potential milestones related to OPTIC 2L T315i+ 200 Total 3rd line + 1,400 Current eligible pool patients 21
22 DEVELOPMENT/PIPELINE Brigatinib: Development programs ALTA 1L Goals Expand market potential through front line indication Potential for long duration of treatment enhances revenue potential H2H superiority data would further strengthen efficacy positioning Confirmatory study for FDA approval Annual Incidence/ Number of Switches * 1st Line 4,300 2nd Line 2,500 3rd Line+ 1,300 SOURCE: *SEER Cancer Statistics Review ; UpToDate; 2012 SEER Data (Cancer Statistics Review, ); Cancer.gov; ARIAD internal assumptions, Applies mutation and testing rate. Stage IV only and assumes 85% testing by 2017, Kantar Health Epi Report 2015; eligible patients is reflective of all patients who would be candidates for ALK treatment 22
23 DEVELOPMENT/PIPELINE AP32788 Program Orally active TKI precision therapy Unique profile demonstrated against EGFR and HER2 Exon 20 mutations No current approved targeted treatments Estimated 6,000 US patients Phase I/II clinical study underway Initial data expected next year Crystal structure of EGFR in complex with AP
24 ARIAD s new strategy Commercial Maximization Development/Pipeline Science & Discovery Engine for new potential products expand development pipeline World class capability in designing precision cancer therapies Expanding platform into small molecule immuno oncology Lean, Cost efficient Structure 24
25 SCIENCE & DISCOVERY Discovery platform Precision therapies targeting rare cancers Kinase inhibitors Validated targets low target based risk Potential rapid clinical proof of concept Potential streamlined development: ~4 5 years first in human to approval Leveraging precision, small molecule platform into immuno oncology Genetically validated kinase target; in cell assays, inhibition stimulates T cell activation; similar to PD 1 antibody levels Resistance mapping Innovative chemistry 25
26 ARIAD s new strategy Commercial Maximization Development/Pipeline Science & Discovery Lean, Cost efficient Structure Rare cancer model designed for efficient commercialization/r&d Operations limited to US Lean G&A/headquarter functions 26
27 LEAN, COST EFFICIENT STRUCTURE Lean, cost efficient structure Incyte transaction: $65 mil annual operating cost savings Reduced 90 HQ positions critically evaluated every role in the company Reinvested in new customer facing positions Doubled the US customer facing roles 2016 vs Focused R&D spend on critical and necessary activities Shared development costs with partners (Incyte and Otsuka) Reduced G&A expenses in line with a leaner, more efficient organization Direct positive impact on shareholder value from reduced costs 27
28 SUMMARY Looking ahead: Expanding addressable patient populations Eligible US Patient Population (Incidence) Current/Initial Potential Future ~1,000 2,000 ~3,000 4,000 Brigatinib ~4,000 ~7,000 8,000 AP32788 NA ~6,000 28
29 SUMMARY Cultural DNA elements ACCOUNTABILITY Own It We always meet our plans and commitments PASSION FOR PATIENTS Feel It We aim to have every appropriate patient treated with our therapies and supported by our programs SENSE OF URGENCY Make It Happen We make every day count with our actions, from our labs to the field 29
30 Strong and diverse executive management team Paris Panayiotopoulos President and Chief Executive Officer Tim Clackson, Ph.D. President, R&D, CSO Jennifer Herron EVP, Chief Commercial Officer Hugh Cole SVP, Chief Business Officer Manmeet S. Soni EVP, Chief Financial Officer Jayne Gansler SVP, Human Resources Daniel Bollag SVP, Regulatory Affairs & Quality Elona Kogan, Esq. SVP, General Counsel 30
31
Path to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationGlobal Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)
Merck Media: Markus Talanow +49 6151 72 7144 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 News Release April 7, 2015 Not
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationForward Looking Statements and Further Information
JANUARY 2015 [ 1 ] Forward Looking Statements and Further Information SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More information